Atossa Genetics Inc. (NASDAQ:ATOS) Receives Average Recommendation of “Hold” from Analysts

Shares of Atossa Genetics Inc. (NASDAQ:ATOS) have been given a consensus recommendation of “Hold” by the five analysts that are currently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, two have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $36.3333.

ATOS has been the subject of a number of research reports. Ascendiant Capital Markets lowered their target price on Atossa Genetics from $120.00 to $24.00 and set a “buy” rating for the company in a research note on Friday, April 10th. Weiss Ratings raised Atossa Genetics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. Finally, HC Wainwright increased their target price on Atossa Genetics to $25.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th.

Atossa Genetics Price Performance

Shares of ATOS stock opened at $5.11 on Thursday. The stock has a market cap of $44.00 million, a PE ratio of -1.59 and a beta of 1.24. The stock has a 50-day moving average of $5.28 and a 200-day moving average of $7.29. Atossa Genetics has a one year low of $3.76 and a one year high of $19.35.

Atossa Genetics (NASDAQ:ATOS) last announced its quarterly earnings results on Friday, May 8th. The company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.12). As a group, research analysts anticipate that Atossa Genetics will post -4.41 earnings per share for the current year.

Hedge Funds Weigh In On Atossa Genetics

A number of large investors have recently bought and sold shares of the company. Geode Capital Management LLC boosted its position in Atossa Genetics by 0.7% during the 4th quarter. Geode Capital Management LLC now owns 1,371,909 shares of the company’s stock worth $810,000 after acquiring an additional 9,627 shares during the last quarter. Hudson Bay Capital Management LP acquired a new stake in shares of Atossa Genetics in the 2nd quarter valued at approximately $26,000. Gallagher Capital Advisors LLC acquired a new stake in shares of Atossa Genetics in the 3rd quarter valued at approximately $27,000. JPMorgan Chase & Co. boosted its holdings in shares of Atossa Genetics by 1,294.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock valued at $33,000 after buying an additional 35,474 shares during the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of Atossa Genetics by 55.7% in the 2nd quarter. Bank of America Corp DE now owns 99,601 shares of the company’s stock valued at $83,000 after buying an additional 35,629 shares during the last quarter. Institutional investors and hedge funds own 12.74% of the company’s stock.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.